SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Speculation around a potential buyoutfueled by the CEOs anniversary message and the companys planned ASH presenceis competing with anticipation of a final analysis of SELLASs REGAL Phase 3 trial, last reported at 78 of 80 required events. Some traders read the prolonged trial and managements upbeat tone as encouraging, while others stress that no acquisition, event threshold, or trial result has been confirmed and that the recent price move may be trading without fresh news.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plan to pursue a public listing for its Monee financial-services arm is fueling debate as shares sell off. Some traders see the separation and uncertain timeline as an overhang that could leave Sea with less valuable businesses, while others argue shareholders could benefit from receiving Monee shares or from the business being valued separately.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and outlook dominate discussion, with traders focused on subscriber engagement and growth, ad revenue, and the effect of recent layoffs and content-leadership changes. Views are sharply divided: some see low expectations and a chance for a rebound, while others fear further weakness, citing the stocks decline and its recent post-earnings performance.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for its persistent share-price weakness despite Orladeyo growth, with many traders criticizing management and the Astria acquisition while others argue the business is undervalued. The debate also focuses on upcoming product updates and Navenibart and Netherton data: bulls see potential catalysts, while skeptics question execution and face of HAE competition.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp has driven a sharp rally, with traders focused on the cash proceeds and potential balance-sheet and strategic benefits. The reaction is divided: some see a positive reset, while skeptics worry the divestiture removes a meaningful revenue business and leaves weaker operations and debt concerns.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is selling off despite a quarterly earnings beat and higher full-year guidance, as traders focus on rising costs, weaker cash conversion, lower-margin sales and a loss in its insurance business; some also worry that engines are accumulating at Boeing ahead of aircraft deliveries. The reaction has frustrated bullish traders who see strong demand and orders, while others view the selloff as evidence that profitability and execution matter more than the headline beat.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta is drawing attention as shares rebound while traders look ahead to clinical readouts for its DM1 and FSHD siRNA programs, alongside discussion of Arrowhead data as a possible validation of the technology. Bulls see the pipeline as a potential growth driver, while skeptics say early or preclinical results still need to translate into meaningful patient benefit and question the stocks weak price action.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech-sector rebound is driving attention, with traders describing XBI as breaking out after a sharp pullback and citing renewed buying and possible rotation into biotech. Bulls see a recovery taking hold, while skeptics warn the bounce could fade amid rate and other macro headwinds.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 trial of RAP-219 in bipolar mania met its primary and secondary endpoints, driving a sharp burst of bullish attention. Traders are divided over whether the modest placebo-adjusted improvement and safety and discontinuation concerns make the result less compelling, with some viewing it as proof of concept and others expecting the rally to fade.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being discussed alongside expectations of Republican losses in the midterms and declining confidence in Trump, with many traders blaming the stocks political association and questioning the companys business value. The conversation is predominantly bearish, though some traders see a possible short-term bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Shares of BranchOut Food Surge 89% in a Year

BOF's 89% rally reflects expanding ingredient sales, recurring retail programs and rising factory utilization that could support margin recovery.

The Zacks Analyst Blog Highlights ExxonMobil, Automatic Data Processing and Cadence Design, BranchOut Food

XOM, ADP, CDNS and BOF feature in Zacks research, with AI, operational efficiency, recurring revenue and growth opportunities shaping their outlooks.

Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence

ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.

BOF Stock Falls 12.1% as Q2 Loss Widens Y/Y Despite Sales Gain

BranchOut Food posts record Q2 revenues, but weaker margins and a wider loss weigh on the BOF stock as management targets a stronger Q4.

Branchout Food Reports Q2 2026 Results: Full Earnings Call Transcript

Branchout Food (NASDAQ:BOF) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut

AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.

Top Research Reports for Applied Materials, Mastercard & AbbVie

Applied Materials is riding AI-driven chip demand, but can record margins, new products and China-related risks shape its next phase of growth?

2 Food For Thought Microcaps with Outperform Ratings

BranchOut Food Q1 Loss Widens Y/Y Amid Inventory Build for Q2 Growth

BOF posts a wider y/y loss in Q1 as revenues fall. But management expects record Q2 sales, driven by major customer deliveries and production growth.

BranchOut Food (NASDAQ:BOF) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen raised BranchOut Food from a 'sell' rating to a 'hold' rating in a report on Saturday...

BranchOut Food, Inc. engages in the development, marketing, sale, and distribution of plant-based, dehydrated fruit, and vegetable snacks and powders. Its products include pineapple chips, chewy banana bites, crunchy strawberry halves, bell pepper crisps, and carrot sticks. The company was founded by Eric Healy and David Israel on February 21, 2017 and is headquartered in Bend, OR.

BranchOut Food Inc

BranchOut Food Stock Surges On Sales Growth Projection: Retail's Bullish

Equity

Neutral Sentiment

Shares of BranchOut Food Inc. ($BOF) were up 7% on Wednesday after the company posted sales projections of $9 million for H1 2025, lifting retail mood.The increase in revenue would be a 218% year-over-year increase, according to a company statement. BranchOut is on track to inflect to positive cash flow beginning in Q1 2025, driven by increased demand and cost efficiencies, it added.The growth is fueled by $4 million it expects from one of the largest warehouse clubs, said the company, adding the club has committed to four of its products and is finalizing plans to roll out all five items across four regions.BranchOut has also increased its product count and regional presence, with new partnerships in the Midwest and Northeast regions.“This transformative expansion with one of the nation’s most prestigious retail platforms highlights the value of our GentleDry technology, which delivers innovative, first-to-market snacks that excel in flavor, nutrition, and texture,” Eric Healy, CEO of BranchOut Food. said. “This partnership not only validates our product quality but also positions BranchOut as a leader in the premium snack category, driving broader market adoption and long-term growth.”BranchOut’s fully-commissioned 50,000-square-foot Peru facility has over $40 million in annual production capacity.Retail sentiment on Stocktwits was largely bullish.<stembedurl>https://stocktwits.com/Samuinvest/message/600119371</stembedurl><stembedurl>https://stocktwits.com/teksviler/message/600212159</stembedurl>BranchOut Food, which has 17 patents, is an international food technology company that produces dehydrated fruit and vegetable-based products.<a href="https://stocktwits.com/symbol/BOF">BranchOut Food stock</a> is up 4.62%For updates and corrections, email newsroom[at]stocktwits[dot]com.

BranchOut’s 50,000-square-foot Peru facility has over $40 million in annual production capacity.

TIDAL ETF TRUST II - Carbon Collective Climate Solutions U.S. Equity ETF

Vanguard Extended Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$BOF This q can go two ways.  Either management straightened up their act and we have a record q, or they squander more money, have more sus random losses to cover, and issue more debt almost immediately.  Their silence isn't doing investors any favors as we eat the warrants and shares issued.

hiddenFigure

$BOF Nope, flipped those shares right on back out.  No pr with a$50m shelf offering.  Geez.  I'll hold some, but I'm not sure management has what it takes any more.

$BOF outside of the filing, anyone aware of the company actually selling shares, or plans to do so soon?

Blions

$BOF "The Stock Market is a Device for Transferring Money from the Impatient to the Patient" Sell them shares boys and girls.

anon anon

$BOF Damn, they didn't even drop their usual monthly news.  Management just giving out beatings until morale improves I guess.  Hopefully this was a wake up call for them and they got laser focused.  My remaining shares her are the only thing dragging my shit down lately.

Feed

News

Sentiment

Fundamentals

Info

BOF BranchOut Food Inc

Fundamentals

Latest BOF News